Ezlopitant

Ezlopitant
Clinical data
Other names	CJ-11,974; (2S,3S)-2-Diphenylmethyl-3-[(5-isopropyl-2-methoxybenzyl)amino]quinuclidine
Routes of; administration	By mouth
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Pharmacokinetic data
Excretion	Urine (32%), Feces (51%)
Identifiers
	IUPAC name (2S,3S)-2-Benzhydryl-N-[(5-isopropyl-2-methoxy-phenyl)methyl]quinuclidin-3-amine;
CAS Number	147116-64-1;
PubChem CID	188927;
IUPHAR/BPS	5751;
ChemSpider	164166;
UNII	3L098A8MPY;
ChEMBL	ChEMBL515966;
CompTox Dashboard (EPA)	DTXSID601318557 ;
Chemical and physical data
Formula	C31H38N2O
Molar mass	454.658 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1ccc(cc1CN[C@H]2C3CCN(CC3)[C@H]2C(c4ccccc4)c5ccccc5)C(C)C;
	InChI InChI=1S/C31H38N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,22,25,29-32H,16-19,21H2,1-3H3/t30-,31-/m0/s1; Key:XPNMCDYOYIKVGB-CONSDPRKSA-N;

Ezlopitant (INN,^[1] code name CJ-11,974) is an NK₁ receptor antagonist.^[2]^[3]^[4] It has antiemetic and antinociceptive effects.^[5]^[6] Pfizer was developing ezlopitant for the treatment of irritable bowel syndrome but it appears to have been discontinued.^[2]

References

^ ^a ^b "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 44" (PDF). World Health Organization. pp. 194–5. Retrieved 17 November 2016.
^ ^a ^b Evangelista S (October 2001). "Eziopitant. Pfizer". Current Opinion in Investigational Drugs. 2 (10): 1441–3. PMID 11890362.
^ Diemunsch P, Grélot L (September 2000). "Potential of substance P antagonists as antiemetics". Drugs. 60 (3): 533–46. doi:10.2165/00003495-200060030-00002. PMID 11030465. S2CID 25136161.
^ Giardina GA, Gagliardi S, Martinelli M (August 2003). "Antagonists at the neurokinin receptors--recent patent literature". IDrugs: The Investigational Drugs Journal. 6 (8): 758–72. PMID 12917772.
^ Tsuchiya M, Fujiwara Y, Kanai Y, et al. (November 2002). "Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret". Pharmacology. 66 (3): 144–52. doi:10.1159/000063796. PMID 12372904. S2CID 37936941.
^ Tsuchiya M, Sakakibara A, Yamamoto M (January 2005). "A tachykinin NK1 receptor antagonist attenuates the 4 beta-phorbol-12-myristate-13-acetate-induced nociceptive behaviour in the rat". European Journal of Pharmacology. 507 (1–3): 29–34. doi:10.1016/j.ejphar.2004.11.028. PMID 15659291.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Clinical data

Other names	CJ-11,974; (2S,3S)-2-Diphenylmethyl-3-[(5-isopropyl-2-methoxybenzyl)amino]quinuclidine^[1]
Routes of administration	By mouth
ATC code	none
Legal status
Legal status	In general: uncontrolled
Pharmacokinetic data
Excretion	Urine (32%), Feces (51%)
Identifiers
IUPAC name (2S,3S)-2-Benzhydryl-N-[(5-isopropyl-2-methoxy-phenyl)methyl]quinuclidin-3-amine
CAS Number	147116-64-1
PubChem CID	188927
IUPHAR/BPS	5751
ChemSpider	164166
UNII	3L098A8MPY
ChEMBL	ChEMBL515966
CompTox Dashboard (EPA)	DTXSID601318557
Chemical and physical data
Formula	C₃₁H₃₈N₂O
Molar mass	454.658 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES COc1ccc(cc1CN[C@H]2C3CCN(CC3)[C@H]2C(c4ccccc4)c5ccccc5)C(C)C
InChI InChI=1S/C31H38N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,22,25,29-32H,16-19,21H2,1-3H3/t30-,31-/m0/s1 Key:XPNMCDYOYIKVGB-CONSDPRKSA-N